PLM Fleet Opens New Branches in Rochester and Philadelphia
'PLM is proud to open these new branches in Philadelphia and Western New York, which marks a significant milestone in our commitment to be the leader in refrigerated fleet management,' said Jerry Keane, VP and General Manager, Rental.
PLM Fleet has the nation's largest and most diverse selection of refrigerated equipment, ranging in lengths from 28 to 53 feet, with single-temperature, multiple-temperature, or electric-only, including versatile liftgate options. Every rental includes PLM's On-Site Mobile maintenance and 24/7 emergency break-down service. PLM offers pick up and drop off service, and a dedicated team of in-house fleet managers. With the innovative PLMServiceCode™, customers can request and monitor all service requests, track repairs to completion, and view their trailer licensing and registration.
'PLM is proud to open these new branches in Philadelphia and Western New York, which marks a significant milestone in our commitment to be the leader in refrigerated fleet management,' said Jerry Keane, VP and General Manager, Rental. 'This expansion strengthens our ability to provide customers with more cost-effective and timely access to trailers, while offering a broad range of specifications tailored to meet the distinct operational needs of their businesses.'
The new PLM branches are located at:
8330 State Road, Philadelphia, PA 19136
1280 Jefferson Road, Rochester, NY 14623
PLM Fleet has a network of 35 branches in all the key markets nationwide. At all of PLM's branches, customers can rent equipment for a year, month or even one day. With over 15,000 units, PLM has the nation's largest and most versatile selection of refrigerated equipment. Known for innovating refrigerated fleet management, PLM can be found at plmfleet.com.
About PLM Fleet, LLC
PLM Fleet ® is the largest nationwide, technology-driven company dedicated to refrigerated trailer leasing and cold supply chain solutions. Located in the state-of-the-art fleet solutions center in Newark, NJ, PLM has the largest assortment of refrigerated trailers in the U.S. Visit plmfleet.com to review all the financing, technology and services that help our customers improve fleet and product lifecycle efficiencies and cost savings in the cold supply chain.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
4 hours ago
- Miami Herald
Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESS Newswire / August 1, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Atossa Therapeutics, Inc. (Nasdaq:ATOS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, August 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interviews in their entirety at: CLDI: In an exclusive interview, Eric Poma, Ph.D., CEO of Calidi Biotherapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss Calidi's pioneering approach to precision genetic medicine, enabled by its proprietary RedTail platform-an engineered, systemically delivered viral therapy designed to reach metastatic sites and deliver genetic medicines to treat tumors. The platform cloaks potent genetic payloads, such as IL-15 superagonist, within a human-derived envelope, allowing the virus to evade immune detection and circulate throughout the body. Preclinical data showcased at AACR and ASCO demonstrated that a single dose of Calidi's lead candidate, CLD-401, not only eliminated metastatic tumors but also primed immune memory, offering the potential to prevent recurrence. With its scalable, non-integrating viral backbone and ability to deliver multiple genetic payloads, RedTail positions Calidi to address a vast oncology market projected to exceed $560 billion by 2033. The company is advancing toward IND filing in 2026, while exploring strategic pharma partnerships to support global commercialization. Calidi's capital-efficient business model, strengthened balance sheet, and next-generation pipeline targeting both cancer and autoimmune diseases highlight its strong potential to deliver value to shareholders. Dr. Steven Quay, CEO of Atossa Therapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss Atossa's strategic approach to redefining breast cancer treatment through its lead clinical candidate, (Z)-endoxifen - a next-generation SERM with best-in-class potential. With a focus on metastatic breast cancer, where current therapies often fall short, Atossa is advancing multiple Phase 2 studies that demonstrate strong clinical activity, improved tolerability, and a favorable safety profile. The presentation will highlight recent progress across key development programs, upcoming milestones, and how the Company's differentiated science and capital-efficient model are designed to deliver both clinical impact and long-term shareholder value. CLDI and ATOS are clients of RedChip Companies. Please read our full disclosure at About Calidi Biotherapeutics Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company pioneering the development of targeted therapies that can deliver genetic medicines to sites of disease. The company's proprietary Redtail platform represents a decade of development and expertise in designing viral vectors that can evade immune detection allowing for systemic delivery and distal sites of disease in oncology and, potentially, other indications. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent gene therapies to metastatic locations. The lead candidate from the Redtail platform, currently in IND-enabling studies, targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need. Additionally, Calidi is developing protected virotherapies, in clinical-stage, for intratumoral and localized administration, focusing on a subset of injectable cancer indications. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit About Atossa Therapeutics Atossa Therapeutics, Inc. (Nasdaq:ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The company's lead product candidate, (Z)-endoxifen, is a highly potent SERM designed for use across the breast cancer spectrum, including prevention, neoadjuvant, adjuvant, and metastatic settings. Atossa is committed to advancing its robust clinical research programs to improve patient outcomes while creating sustainable value for shareholders. For more information, visit About RedChip Companies RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights. To learn more about RedChip's products and services, please visit: "Discovering Tomorrow's Blue Chips Today"™ Follow RedChip on LinkedIn: Follow RedChip on Facebook: Follow RedChip on Instagram: Follow RedChip on Twitter: Follow RedChip on YouTube: Follow RedChip on Rumble: Subscribe to our Mailing List: Contact: Dave GentryRedChip Companies Inc.1-407-644-4256info@ SOURCE: RedChip Companies, Inc.
Business Wire
5 hours ago
- Business Wire
BioConsortia Closes Financing to Accelerate Launch of Next-Generation Nitrogen-Fixing Biofertilizer and Fuel Global Expansion
BUSINESS WIRE)--BioConsortia, Inc., a leader in microbial innovation for sustainable agriculture, announced today it has secured $15 million in funding from its long-standing internal investors, led by Otter Capital and affiliated funds. 'This investment, one in a series of recurring financings from our internal investors, reflects their deep confidence in BioConsortia's science, strategy, and commercial momentum,' said Marcus Meadows-Smith, BioConsortia's CEO. 'Their investments total $95 million and bring BioConsortia to this exciting moment in the company's history.' The new funding will accelerate the global launch of Always-N™, BioConsortia's groundbreaking nitrogen-fixing seed treatment for industrial corn and support continued expansion of its discovery and development engine at the company's Davis, California headquarters. Always-N enables farmers to maintain crop yields while reducing reliance on synthetic nitrogen fertilizers—significantly lowering greenhouse gas emissions and improving soil health. Applied as a seed treatment, Always-N delivers consistent field performance and is the only nitrogen-fixing biofertilizer combining advanced gene editing and extended viability exceeding two years. "Synthetic nitrogen fertilizers are essential to modern agriculture, but their overuse comes at a steep environmental cost,' said Meadows-Smith. 'With Always-N, we offer a powerful, sustainable alternative—backed by cutting-edge science and built for real-world performance.' Roughly half of applied synthetic nitrogen is never absorbed by crops. Instead, it runs off into waterways or is broken down in soil, releasing nitrous oxide—a greenhouse gas 300 times more potent than CO₂. As regulatory and market pressure builds for climate-smart farming, demand for sustainable alternatives like Always-N is growing rapidly. Following its successful commercial debut in New Zealand in 2024, Always-N is now preparing for broader market entry, supported by key global partners including The Mosaic Company in row crops in the Americas. The new funding enables BioConsortia to scale manufacturing, build inventory, and expand market access in anticipation of the upcoming growing season. Always-N is powered by BioConsortia's discovery and development platform - an integrated engine using proprietary tools for microbial discovery, selection, and optimization. It begins with Advanced Microbial Selection™ (AMS) to identify high-performing plant-associated microbes, then uses GenExpress™ and GenePro™ tools to enhance traits such as nitrogen fixation, disease and pest control, and shelf-life. In addition to Always-N™, BioConsortia is advancing a robust pipeline of next-generation biostimulants, fungicides, nematicides, and insecticides—engineered for extended shelf life, ease of use, and superior field efficacy. Since its founding in 2014, BioConsortia has validated its platform across diverse crops, geographies, and soil types. Field trials have consistently demonstrated the efficacy of its microbial biofertilizers, fungicides, nematicides, and insecticides—delivering growers new tools for sustainable, high-yield farming. About BioConsortia At BioConsortia, we are pioneering the next generation of agricultural biologicals through cutting-edge microbial gene editing. Our breakthroughs in editing only the most stable microbes unlock unprecedented performance in nitrogen fixation, biocontrol, and biostimulants—delivering solutions that are more effective, more consistent, and easier to use than anything on the market today. By precisely enhancing natural microbial traits, we're creating products that outperform both traditional chemicals and first-generation biologicals—with longer shelf life, extended life on seed, robust field efficacy, and compatibility with existing farm systems. Our AMS platform supports rapid discovery and development of superior wild type microbial products, and our gene-edited innovations redefine what's possible in sustainable agriculture. Since its founding in 2014, BioConsortia has built a reputation for delivering science-driven, field-proven solutions across a wide range of crops, geographies, and growing conditions. Today, the company stands at the forefront of the agricultural biologicals revolution—offering farmers the tools to grow more with less, and do so sustainably.
%3Amax_bytes(150000)%3Astrip_icc()%2FTAL-avis-first-AVISPREMIUM0725-33ae48126d69457ea3830b63727232d6.jpg&w=3840&q=100)
Travel + Leisure
6 hours ago
- Travel + Leisure
Avis' New Premium Service Is a VIP Experience With a Personal Concierge—and No Shuttle or Counter Required
Avis Budget Group introduced a brand-new luxury service this week, allowing customers to skip the time-consuming airport shuttle and rental car counter. The new curbside service, called Avis First, will bring rental cars directly to customers at the airport terminal, according to the company. Currently, the new service is available at major airports in Denver; Honolulu; and Palm Beach, Florida. 'I remember the days of hauling strollers, car seats, and luggage through an airport tram, and that can be tough," Avis CEO Brian Choi told Travel + Leisure . "We think this makes a huge difference." Choi said he views the Avis First service as a brand-new category in the rental car market, offering premium, concierge-level customer service. When travelers sign up at the airport, they are assigned a personal concierge and their chosen vehicle is brought right to the terminal. Customers also don't need to deal with the pesky task of refilling the tank or prepaying for gas as Avis just charges the market price for whatever was used. All of the cars used for the Avis First program are 2025 models with low mileage. Beyond airports, the service is offered in select locations within the New York City-area, including in Manhattan, Hoboken, and Jersey City; as well as in Chicago, San Francisco, Miami, Orlando, Seattle, and Washington, D.C. For neighborhood renters—often families or people traveling for a road-trip—picking up a rental car can be difficult. But with Avis First, the company said it aims to simplify that experience and provide new options for time-conscious travelers seeking a personalized experience. While the perks are significant, travelers can expect to pay a higher price for the experience. An Avis First rental from Sept. 8 to Sept. 12 at Denver International Airport (DEN), for example, will set travelers back $547 for a Mercedes-Benz GLS 450 SUV, according to a search by T+L at the time of writing. In comparison, renting a Jeep Grand Cherokee in the company's "Standard Elite SUV" category will only cost travelers $435 for the same time period. Travelers hoping to save money on a car rental can check their own airline loyalty programs for discounts, search third-party discount sites, keep their eyes peeled for junk fees, set a designated driver, and even keep an eye out for available coupons. Generally (though not always), renting at the airport can cost so travelers who hope to save should instead opt for an off-airport location.
